Secukinumab in Pediatric Patients with Plaque Psoriasis - Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials - American Journal of Clinical Dermatology.pdf
Mahe E. Optimal management of plaque psoriasis in adolescents: current perspectives. Psoriasis (Auckl). 2020;10:45–56.
Branisteanu DE, Georgescu S, Serban IL, Pinzariu AC, Boda D, Maranduca MA, et al. Management of psoriasis in children. Exp Ther Med. 2021;22(6):1429. DOI: 10.3892/etm.2021.10864
Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guerin A, et al. Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol. 2018;17(2):187–94.
Salman A, Yucelten AD, Sarac E, Saricam MH, Perdahli-Fis N. Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study. An Bras Dermatol. 2018;93(6):819–23. DOI: 10.1590/abd1806-4841.20186981
Lansang P, Bergman JN, Fiorillo L, Joseph M, Lara-Corrales I, Marcoux D, et al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol. 2020;82(1):213–21. DOI: 10.1016/j.jaad.2019.05.056
Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373–84. DOI: 10.1007/s40272-015-0137-1
Zitouni J, Beauchet A, Curmin R, Di Lernia V, Bursztejn AC, Mazereeuw-Hautier J, et al. Effectiveness and safety of adalimumab, etanercept and ustekinumab for severe psoriasis in children under 12 years of age: a French-Italian daily practice cohort (BiPe Jr). Paediatr Drugs. 2022;24(3):281–92. DOI: 10.1007/s40272-022-00501-6
Goenaga-Vázquez Y, Lauck KC, Grabell D, Hebert AA. 16403 Therapeutic challenges in managing pediatric psoriasis. J Am Acad Dermatol. 2020;83(6):AB178.
Peris K, Fortina AB, Bianchi L, Fabbrocini G, Gisondi P, Balato A, et al. Update on the management of pediatric psoriasis: an Italian consensus. Dermatol Ther (Heidelb). 2022;12(8):1753–75. DOI: 10.1007/s13555-022-00758-2
Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161–73. DOI: 10.1111/jdv.16124
Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate-to-severe plaque psoriasis. J Dermatol Treat. 2020;31(8):769–75. DOI: 10.1080/09546634.2019.1626973
Cosentyx PI U 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125504s043lbl.pdf. Accessed 01 May 2022.
Cosentyx SmPC. 2021.https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf. Accessed 26 July 2021.
Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, et al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1):122–30. DOI: 10.1016/j.jaad.2021.08.066
Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, et al. Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study. Paediatr Drugs. 2022;24(4):377–87. DOI: 10.1007/s40272-022-00507-0
Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938–47. DOI: 10.1111/jdv.17002
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE). 2011. https://ClinicalTrials.gov/show/NCT01365455. Accessed 26 July 2021.
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) 2012. https://ClinicalTrials.gov/show/NCT01636687. Accessed 26 July 2021.
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE). 2011. https://ClinicalTrials.gov/show/NCT01358578. Accessed 26 July 2021.
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: response at 12 Weeks (FEATURE). 2012. https://ClinicalTrials.gov/show/NCT01555125. Accessed 26 July 2021.
Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the US population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146(7):486–92. DOI: 10.7326/0003-4819-146-7-200704030-00004
Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603. DOI: 10.1016/j.jaad.2015.07.002
Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. DOI: 10.1186/s13075-019-1882-2
Gottlieb AB, Deodhar A, McInnes IB, Baraliakos X, Reich K, Schreiber S, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102:adv00698. DOI: 10.2340/actadv.v102.563
Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol. 1996;157(8):3223–7. DOI: 10.4049/jimmunol.157.8.3223
Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285–94. DOI: 10.1016/j.immuni.2005.01.011
van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83-98.e4. DOI: 10.1016/j.jaad.2016.03.024
Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the USA: 2005–09. Br J Dermatol. 2014;170(2):366–73. DOI: 10.1111/bjd.12744
Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS. Psoriasis and vascular disease—risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011;26(9):1036–49. DOI: 10.1007/s11606-011-1698-5
Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417–23. DOI: 10.1001/jamadermatol.2018.3631
Kircik L, Fowler J, Weiss J, Meng X, Guana A, Nyirady J. Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6(4):627–38. DOI: 10.1007/s13555-016-0139-0
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. DOI: 10.1056/NEJMoa1314258
Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–90. DOI: 10.1111/jdv.12751
